WHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO’s work on R&D
Saturday, 28 May 2016
WHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO’s work on R&D
WHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license
For more information, contact:
(U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670
(Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org
(Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com
(More on Colombia here: /colombia)
28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug
Contact:
(U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670
(Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org
(Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com
(More on Colombia here: /colombia)
Washington, DC — Today, 28 organizations that support the advancement of public health, as well as the successful continuation of the peace process in Colombia, urged President Obama to voice U.S. support for Colombia’s right to grant a compulsory license on an expensive leukemia drug. Continue Reading
HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement
The following is the intervention on behalf of Stichting Health Action International (HAI) at 69th World Health Assembly, Agenda Item 16.2: Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination – Report of the open-ended meeting of Member States.
KEI worked with HAI on the statement, and it was delivered by James Love
Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug
(More on Colombia here: /colombia)
In response to reports of USTR pressure on Colombia’s potential compulsory license for imatinib, Senators Sherrod Brown, D-Ohio, and Bernie Sanders, I-Vt., have sent a letter to USTR objecting “to any efforts to protect the public health of Colombians in a way that is appropriate, effective, and consistent with the country’s trade and public health obligations,” and condemning as unconscionable “that any representatives of the U.S. government would threaten to rescind funding for Colombia’s peace iniative if a compulsory license for Glivec were issued.” Continue Reading
15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia
Yesterday, fifteen House Democrats sent a letter to Ambassador Michael Froman at the United States Trade Representative to express serious concern that the United States officials have been pressuring Colombia to abandon the process of issuing a compulsory license on imatinib. The letter can be read here.
Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib
Yesterday, Colombia’s W Radio aired an interview with Senator Orrin Hatch, R-Utah, where he was asked about the reports of pressure on Colombia from the Senate Finance Committee, which he chairs, with regard to the compulsory license process for the expensive leukemia drug, imatinib.
WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies
(More on Colombia here: /colombia)
On May 24, 2016, Colombia’s Minister of Health, Alejandro Gaviria, made an intervention at the World Health Assembly that referred to the pressure Colombia has been facing with regard to the potential compulsory license for imatinib and called for the WHO to support members to ensure sustainable development through the regulation of pharmaceutical monopolies and promoting competition, transparency, and the rational use of drugs.
Continue Reading
WHO at the crossroads: negotiations to fund global R&D mired in eight pages of [bracketed] text
On Friday, 20 May 2016, the World Health Organization (WHO) published document A69/40, Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination — Report of the open-ended meeting of Member States. This… Continue Reading
Background FAQ on Glivec (imatinib) compulsory license in Colombia
(More on Colombia here: /colombia) For more information, contact: (U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670 (Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org (Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com Frequently Asked Questions What is happening in Colombia… Continue Reading